<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-11132R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0008025</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Neurological Disorders</subject><subject>Neurological Disorders/Movement Disorders</subject><subject>Neurological Disorders/Neurogenetics</subject><subject>Pathology/Cellular Pathology</subject><subject>Pathology/Histopathology</subject></subj-group></article-categories><title-group><article-title>Formation of Polyglutamine Inclusions in a Wide Range of Non-CNS Tissues in the <italic>Hdh</italic>Q150 Knock-In Mouse Model of Huntington's Disease</article-title><alt-title alt-title-type="running-head">HD Mice: Non-CNS Pathology</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moffitt</surname><given-names>Hilary</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>McPhail</surname><given-names>Graham D.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Woodman</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hobbs</surname><given-names>Carl</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bates</surname><given-names>Gillian P.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Medical and Molecular Genetics, King's College London School of Medicine, London, United Kingdom</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Division of Cellular Pathology, Barts and the London NHS Trust, Royal London Hospital, London, United Kingdom</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Wolfson Centre for Age-Related Diseases, Kings College London School of Medicine, London, United Kingdom</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Okazawa</surname><given-names>Hitoshi</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Tokyo Medical and Dental University, Japan</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>gillian.bates@kcl.ac.uk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: HM GPB. Performed the experiments: HM GDM. Analyzed the data: HM GDM. Contributed reagents/materials/analysis tools: BW CH. Wrote the paper: HM GPB.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>30</day><month>11</month><year>2009</year></pub-date><volume>4</volume><issue>11</issue><elocation-id>e8025</elocation-id><history><date date-type="received"><day>19</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>Moffitt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Huntington's disease (HD) is an inherited progressive neurodegenerative disorder caused by a CAG repeat expansion in the ubiquitously expressed <italic>HD</italic> gene resulting in an abnormally long polyglutamine repeat in the huntingtin protein. Polyglutamine inclusions are a hallmark of the neuropathology of HD. We have previously shown that inclusion pathology is also present in the peripheral tissues of the R6/2 mouse model of HD which expresses a small N-terminal fragment of mutant huntingtin. To determine whether this peripheral pathology is a consequence of the aberrant expression of this N-terminal fragment, we extend this analysis to the genetically precise knock-in mouse model of HD, <italic>Hdh</italic>Q150, which expresses mutant mouse huntingtin.</p></sec><sec><title>Methodology/Principal Findings</title><p>We have previously standardized the CAG repeat size and strain background of the R6/2 and <italic>Hdh</italic>Q150 knock-in mouse models and found that they develop a comparable and widespread neuropathology. To determine whether <italic>Hdh</italic>Q150 knock-in mice also develop peripheral inclusion pathology, homozygous <italic>Hdh</italic><sup>Q150/Q150</sup> mice were perfusion fixed at 22 months of age, and tissues were processed for histology and immunohistochemistry with the anti-huntingtin antibody S830. The peripheral inclusion pathology was almost identical to that found in R6/2 mice at 12 weeks of age with minor differences in inclusion abundance.</p></sec><sec><title>Conclusions/Significance</title><p>The highly comparable peripheral inclusion pathology that is present in both the R6/2 and <italic>Hdh</italic>Q150 knock-in models of HD indicates that the presence of peripheral inclusions in R6/2 mice is not a consequence of the aberrant expression of an N-terminal huntingtin protein. It remains to be determined whether peripheral inclusions are a pathological feature of the human disease. Both mouse models carry CAG repeats that cause childhood disease in humans, and therefore, inclusion pathology may be a feature of the childhood rather than the adult forms of HD. It is important to establish the extent to which peripheral pathology causes the peripheral symptoms of HD from the perspective of a mechanistic understanding and future treatment options.</p></sec></abstract><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Huntington's disease (HD) is an autosomal dominant late-onset progressive neurodegenerative disorder with a mean age of onset of 40 years. Symptoms include motor disorders, psychiatric disturbances, cognitive decline and weight loss. Disease duration is 15 &#x02013;20 years and there are no effective disease modifying treatments <xref ref-type="bibr" rid="pone.0008025-Bates1">&#x0005b;1&#x0005d;</xref>. The HD mutation is an expanded CAG repeat in the <italic>HD</italic> gene that is translated into a polyglutamine (polyQ) repeat in the huntingtin (Htt) protein <xref ref-type="bibr" rid="pone.0008025-Huntingtons1">&#x0005b;2&#x0005d;</xref>. Unaffected individuals have (CAG)<sub>6&#x02013;35</sub> repeats, whilst disease causing alleles of (CAG)<sub>40</sub> and above are fully penetrant <xref ref-type="bibr" rid="pone.0008025-Rubinsztein1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Myers1">&#x0005b;4&#x0005d;</xref>. Age of symptom onset can range from early childhood to extreme old age with repeats of (CAG)<sub>75</sub> and above invariably causing the childhood form of the disease <xref ref-type="bibr" rid="pone.0008025-Myers1">&#x0005b;4&#x0005d;</xref>. Neuropathologically, the disease is characterized by global brain atrophy <xref ref-type="bibr" rid="pone.0008025-Henley1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Kloppel1">&#x0005b;6&#x0005d;</xref>, neuronal cell loss in the striatum, cortex and other brain regions and the deposition of nuclear and cytoplasmic polyQ aggregates <xref ref-type="bibr" rid="pone.0008025-DiFiglia1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Gutekunst1">&#x0005b;8&#x0005d;</xref>.</p><p>Mouse models of HD include transgenic mice that express either N-terminal fragments of, or full-length human Htt, as well as the genetically precise knock-in models, in which CAG repeats in the mutant range have been inserted into the mouse HD gene (<italic>Hdh</italic>) <xref ref-type="bibr" rid="pone.0008025-Menalled1">&#x0005b;9&#x0005d;</xref>. The N-terminal fragment models <xref ref-type="bibr" rid="pone.0008025-Mangiarini1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Schilling1">&#x0005b;11&#x0005d;</xref>, develop early onset HD-related phenotypes with rapid progression which, especially in the case of the R6/2 mouse, has allowed extensive complementary analyses and established this model as a screening tool. We recently conducted a comparison of R6/2 (age 12 weeks) and homozygous <italic>Hdh</italic>Q150 knock-in (<italic>Hdh</italic><sup>Q150/Q150</sup> aged 22 months) mice <xref ref-type="bibr" rid="pone.0008025-Lin1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Woodman1">&#x0005b;13&#x0005d;</xref> at late stage disease (with relatively standardised strain background and CAG repeat size) and found that both models exhibited widespread and comparable brain phenotypes. Nuclear inclusions and neuropil aggregates were distributed throughout all brain regions in both models <xref ref-type="bibr" rid="pone.0008025-Woodman1">&#x0005b;13&#x0005d;</xref>. Microarray expression profiles from both striatum <xref ref-type="bibr" rid="pone.0008025-Kuhn1">&#x0005b;14&#x0005d;</xref> and cerebellum (Luthi-Carter and Bates, unpublished data) of the R6/2 and <italic>Hdh</italic><sup>Q150/Q150</sup> mice were highly correlated. We had attributed these widespread pathologies in the R6/2 mouse brain to the expression of a small N-terminal fragment of Htt and therefore were surprised to find that it was also a feature of the <italic>Hdh</italic><sup>Q150/Q150</sup> mice.</p><p>We have previously reported that polyQ aggregate pathology, in the form of nuclear inclusions, is also present in a wide range of peripheral tissues in the R6/2 mouse <xref ref-type="bibr" rid="pone.0008025-Sathasivam1">&#x0005b;15&#x0005d;</xref> including skeletal muscle and pancreatic islets. Very little is known about whether HD-related pathologies develop in the peripheral tissues of other mouse models of HD, although it has recently been reported that nuclear inclusions are present in the pancreatic islets of the N171-82Q N-terminal fragment model <xref ref-type="bibr" rid="pone.0008025-Martin1">&#x0005b;16&#x0005d;</xref>. The peripheral pathogenesis of HD is of interest because a number of HD symptoms, that could be caused by a peripheral pathology, have been reported including weight loss <xref ref-type="bibr" rid="pone.0008025-Djousse1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Aziz1">&#x0005b;18&#x0005d;</xref>, abnormal skeletal muscle energy metabolism <xref ref-type="bibr" rid="pone.0008025-Lodi1">&#x0005b;19&#x0005d;</xref>, muscle weakness <xref ref-type="bibr" rid="pone.0008025-Busse1">&#x0005b;20&#x0005d;</xref> insulin sensitivity <xref ref-type="bibr" rid="pone.0008025-Lalic1">&#x0005b;21&#x0005d;</xref> and mitochondrial abnormalities in lymphocytes <xref ref-type="bibr" rid="pone.0008025-Panov1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Squitieri1">&#x0005b;23&#x0005d;</xref>. In general, peripheral organs from HD patients have not been collected at <italic>post mortem</italic> and, unless amenable to biopsy, are not available for analysis. To begin to determine whether the peripheral aggregate pathology present in the R6/2 mice has relevance for the human disease, we have conducted a comprehensive investigation of the distribution of polyQ aggregates in the peripheral tissues of the <italic>Hdh</italic>Q150 knock-in model expressing mutant full length Htt at endogenous levels. We find an identical distribution in aggregate pathology between the R6/2 and <italic>Hdh</italic>Q150 models, with only minor differences in aggregate abundance.</p></sec><sec id="s2"><title>Results</title><p>In order to investigate the distribution of inclusions in non-CNS tissue, 22 month old <italic>Hdh</italic><sup>Q150/Q150</sup> mice and littermate controls were perfusion fixed and organs and tissue were removed processed and wax embedded. A 12 week old R6/2 mouse plus wild type littermate was processed alongside for direct comparison. The 5 &#x000b5;m tissue sections were stained with haematoxylin and eosin (H&#x00026;E) for tissue identification and immunostained with the S830 antibody for the identification of inclusions. Tissues and cell types in which inclusions were detected are summarised in <xref ref-type="table" rid="pone-0008025-t001">Table 1</xref> and examples are illustrated in <xref ref-type="fig" rid="pone-0008025-g001">Figure 1</xref>, <xref ref-type="fig" rid="pone-0008025-g002">Figure 2</xref>, <xref ref-type="fig" rid="pone-0008025-g003">Figure 3</xref>, <xref ref-type="fig" rid="pone-0008025-g004">Figure 4</xref>, and <xref ref-type="fig" rid="pone-0008025-g005">Figure 5</xref>. Inclusions were only detected in cell nuclei and in the majority of nuclei there was only one inclusion, but in some cell types: skeletal muscle fibres, liver hepatocytes and connective tissue fibroblasts, there were multiple nuclear inclusions, as in the R6/2 model. We noted considerable variation in the number of nuclear inclusions in the tissues examined between individual <italic>Hdh</italic><sup>Q150/Q150</sup> mice but not in the overall distribution of inclusions.</p><fig id="pone-0008025-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008025.g001</object-id><label>Figure 1</label><caption><title>Nuclear inclusions in the skeletal muscle and liver of <italic>Hdh</italic><sup>Q150/Q150</sup> mice.</title><p>Nuclear inclusions in longitudinal sections of quadriceps muscle are present in <italic>Hdh</italic><sup>Q150/Q150</sup> (A) but absent from wild-type (B) mice. Nuclear inclusions are present in hepatocytes from <italic>Hdh</italic><sup>Q150/Q150</sup> (C) but not in those from wild-type (D) mice and are abundant in an <italic>Hdh</italic><sup>Q150/Q150</sup> intrahepatic bile duct (E). The insert shows a higher magnification of the epithelial cells of the bile duct. Nuclear inclusions are indicated by arrowheads. Scale bar&#x0200a;&#x0003d;&#x0200a;20 &#x000b5;m.</p></caption><graphic xlink:href="pone.0008025.g001"/></fig><fig id="pone-0008025-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008025.g002</object-id><label>Figure 2</label><caption><title>Distribution of nuclear inclusions in the adrenal glands of the <italic>Hdh</italic><sup>Q150/Q150</sup> and R6/2 mice.</title><p>(A) transverse section from an <italic>Hdh</italic><sup>Q150/Q150</sup> mouse illustrating the structure of the adrenal gland. Inclusions present in the outer cortex (B) and inner cortex and medulla (C) from <italic>Hdh</italic><sup>Q150/Q150</sup> mice. Insert in (B) shows an inclusion in a fibroblast from the adrenal capsule. Inclusions are absent from the <italic>Hdh</italic><sup>Q150/Q150</sup> wild type control (D,E). A comparable distribution of inclusions is present in the R6/2 mouse (F,G) except for a greater density of inclusions in the cortex. Nuclear inclusions are indicated by arrowheads. ZG&#x0200a;&#x0003d;&#x0200a;zona glomerulosa, ZF&#x0200a;&#x0003d;&#x0200a;zona fasciculata, M&#x0200a;&#x0003d;&#x0200a;medulla. Scale bar (A)&#x0200a;&#x0003d;&#x0200a;100 &#x000b5;m, scale bar (B&#x02013;G)&#x0200a;&#x0003d;&#x0200a;50 &#x000b5;m.</p></caption><graphic xlink:href="pone.0008025.g002"/></fig><fig id="pone-0008025-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008025.g003</object-id><label>Figure 3</label><caption><title>Pancreatic pathology in the <italic>Hdh</italic>Q150 mouse model.</title><p>Nuclear inclusions were present in the pancreatic islets of <italic>Hdh</italic><sup>Q150/Q150</sup> mice (A) and absent from wild-type controls (B). Insert shows higher magnification image of a nucleus containing a single inclusion indicated by arrow. Electron micrograph showing cytoplasmic detail of &#x003b2;-cells in the islets from an <italic>Hdh</italic><sup>Q150/Q150</sup> mouse (C), a wild-type control (D), and an R6/2 mouse (E). The <italic>Hdh</italic><sup>Q150/Q150</sup> &#x003b2;-cell appears normal as compared to the control. The R6/2 &#x003b2;-cell is atrophied and degranulated in comparison. Arrows indicate &#x003b2;-granules (C&#x02013;E). Pi&#x0200a;&#x0003d;&#x0200a;pancreatic islet, NI&#x0200a;&#x0003d;&#x0200a;nuclear inclusion. Scale bar (A,B)&#x0200a;&#x0003d;&#x0200a;50 &#x000b5;m, scale bar (C,D)&#x0200a;&#x0003d;&#x0200a;1 &#x000b5;m, scale bar (E)&#x0200a;&#x0003d;&#x0200a;2 &#x000b5;m.</p></caption><graphic xlink:href="pone.0008025.g003"/></fig><fig id="pone-0008025-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008025.g004</object-id><label>Figure 4</label><caption><title>Inclusion distribution across the stomach wall in the <italic>Hdh</italic><sup>Q150/Q150</sup> mice.</title><p>(A) Transverse section through the stomach wall of an <italic>Hdh</italic><sup>Q150/Q150</sup> mouse showing structural detail. Inclusions were present in the mucus cells in the gastric gland neck (B), the basal cells of the gastric gland (C), the submucosal ganglia (D), smooth muscle (E), the myenteric ganglia (F), and the serosal ganglia (G) of <italic>Hdh</italic><sup>Q150/Q150</sup> but absent from the wild-type control. A similar distribution was found in R6/2 in comparison to the <italic>Hdh</italic><sup>Q150/Q150</sup>. Nuclear inclusions are indicated by arrowheads. Scale bar (A)&#x0200a;&#x0003d;&#x0200a;100 &#x000b5;m, scale bar (B&#x02013;G)&#x0200a;&#x0003d;&#x0200a;20 &#x000b5;m.</p></caption><graphic xlink:href="pone.0008025.g004"/></fig><fig id="pone-0008025-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008025.g005</object-id><label>Figure 5</label><caption><title>Inclusions are present in the male reproductive glandular epithelium and spleen connective tissue.</title><p>Nuclear inclusions were present in the epithelial cells of the seminal vesicles (A) and the epithelium of the coagulation gland (B) in <italic>Hdh</italic><sup>Q150/Q150</sup> but absent from wild-type mice. A similar distribution was identified in R6/2 mice although the number of affected cells was fewer in number in both cases. Nuclear inclusions were present in connective tissue cells of the spleen capsule from <italic>Hdh</italic><sup>Q150/Q150</sup> mice (C) with a similar distribution in R6/2. Nuclear inclusions are indicated by arrowheads. Scale bar&#x0200a;&#x0003d;&#x0200a;20 &#x000b5;m.</p></caption><graphic xlink:href="pone.0008025.g005"/></fig><table-wrap id="pone-0008025-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008025.t001</object-id><label>Table 1</label><caption><title>Distribution of polyQ inclusions in the peripheral tissues of HD mouse models.</title></caption><alternatives><graphic id="pone-0008025-t001-1" xlink:href="pone.0008025.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Tissue/Organ</td><td align="left" rowspan="1" colspan="1">Inclusion &#x02013; positive cells</td><td align="left" rowspan="1" colspan="1"><italic>Hdh</italic><sup>Q150/Q150</sup></td><td align="left" rowspan="1" colspan="1">R6/2</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Heart</td><td align="left" rowspan="1" colspan="1">Cardiac muscle fibres</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver</td><td align="left" rowspan="1" colspan="1">Hepatocytes</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Bile duct epithelium</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Kidney</td><td align="left" rowspan="1" colspan="1">Tubule/duct epithelial cells</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Interstitial cells</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Glomerular cells</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Adrenal gland</td><td align="left" rowspan="1" colspan="1">Zona glomerulosa</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Zona fasciculate</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Medulla</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Stomach wall</td><td align="left" rowspan="1" colspan="1">Mucosal glands</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Submucosal plexus</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Myenteric plexus</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Serosal ganglia</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Smooth muscle fibres</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Duodenum</td><td align="left" rowspan="1" colspan="1">Submucosal plexus</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Myenteric plexus</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Rectum</td><td align="left" rowspan="1" colspan="1">Submucosal plexus</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Myenteric plexus</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Smooth muscle fibres</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Pancreas</td><td align="left" rowspan="1" colspan="1">Endocrine - islets of Langerhans</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Exocrine - acinar tissue</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Skeletal muscle quadriceps</td><td align="left" rowspan="1" colspan="1">Muscle fibres</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin</td><td align="left" rowspan="1" colspan="1">Nerves Schwann cell</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Testicle</td><td align="left" rowspan="1" colspan="1">Seminiferous tubule epithelium</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">n/a</td></tr><tr><td align="left" rowspan="1" colspan="1">Seminal vesicle</td><td align="left" rowspan="1" colspan="1">Glandular Epithelium</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Coagulation gland</td><td align="left" rowspan="1" colspan="1">Glandular Epithelium</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Brown fat</td><td align="left" rowspan="1" colspan="1">Adipocytes</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Connective tissue</td><td align="left" rowspan="1" colspan="1">Fibroblasts</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Tissue/organ distribution of polyQ inclusions in the R6/2 and <italic>Hdh</italic>Q150 knock-in mouse models of HD. Frequency of inclusion is indicated as follows: &#x0002b; sparse; &#x0002b;&#x0002b; moderate; &#x0002b;&#x0002b;&#x0002b; abundant.</p></fn></table-wrap-foot></table-wrap><sec id="s2a"><title>Distribution of nuclear inclusions in muscle, liver, and kidney</title><p>Nuclear inclusions were found in the skeletal muscle fibres (<xref ref-type="fig" rid="pone-0008025-g001">Figure 1A and 1B</xref>) of the <italic>Hdh</italic><sup>Q150/Q150</sup> mice, with some nuclei containing up to 3 inclusions. Inclusions were also observed in the fibroblasts of the muscle connective tissue. In contrast nuclear inclusions were mostly absent from nuclei of the cardiac muscle fibres and were only observed in a few discrete patches of muscle fibres in the heart wall, a pattern that was identical to that observed in the R6/2 mouse. Nuclear inclusions were also apparent in fibroblasts in the connective tissue of the adventitia of larger cardiac blood vessels. Small numbers of inclusions were noted in the smooth muscle cells (see <xref ref-type="fig" rid="pone-0008025-g004">Figure 4E</xref>) of the stomach wall in a very patchy distribution in both mouse models.</p><p>In the liver, nuclear inclusions were found in the hepatocytes and connective tissue and many of the hepatocyte nuclei had multiple inclusions in a variety of sizes from 0.2 &#x02013; 2 &#x000b5;m (<xref ref-type="fig" rid="pone-0008025-g001">Figure 1C and 1D</xref>). The distribution of inclusions in the hepatocytes was not uniform throughout the liver and staining was patchy. A very small number of Kupffer cells appeared to have inclusions in the nuclei, but identification of cell types in unstained tissue is difficult and a more detailed study will be needed to confirm the identity of these cells. One intrahepatic bile duct present on a slide of a liver preparation from the <italic>Hdh</italic><sup>Q150/Q150</sup> mice contained inclusions in the epithelial cells (<xref ref-type="fig" rid="pone-0008025-g001">Figure 1E</xref>).</p><p>Inclusions were found throughout the kidney, in the cortex, medulla and papilla, in capsule fibroblasts, other connective tissue, interstitial cells, the epithelium of the tubules and ducts and in a few cells of the glomerulus (data not shown). It was not possible to identify which cell type had inclusions in the glomerulus, they may have been podocytes or mesangial cells. A more detailed study would be required to identify the cell type. Overall in the kidney, inclusions were found in low numbers but the numbers increased from the cortex to the papillae. The pattern was similar in both mouse models.</p></sec><sec id="s2b"><title>Nuclear inclusions are most prominent in the medulla of the adrenal glands</title><p>The adrenal gland pathology has been well characterised in the R6/2 mice <xref ref-type="bibr" rid="pone.0008025-Sathasivam1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist1">&#x0005b;24&#x0005d;</xref>. In the adrenal glands of <italic>Hdh</italic><sup>Q150/Q150</sup> mice (<xref ref-type="fig" rid="pone-0008025-g002">Figure 2A&#x02013;2G</xref>) occasional nuclear inclusions were found in the fibroblasts of the gland capsule and very sparse nuclear inclusions in the zona glomerulosa and the zona fasciculata. In contrast there are many large inclusions in the nuclei of the chromaffin cells of the medulla. In R6/2 the distribution and numbers of nuclear inclusions in the connective tissue of the capsule and chromaffin cells of the medulla are similar but there are noticeably more nuclear inclusions in the cells of the zona glomerulosa and the zona fasciculata.</p></sec><sec id="s2c"><title>Pancreatic nuclear inclusion pathology is conserved between the two mouse models, but is not accompanied by &#x003b2;-cell degranulation in the knock-in mice</title><p>In the endocrine pancreas, the principle cell type of the islets of Langerhans, the &#x003b2;-cells, contained nuclear inclusions (<xref ref-type="fig" rid="pone-0008025-g003">Figure 3A</xref>), but the percentage of cells with inclusions varied considerably between individual <italic>Hdh</italic><sup>Q150/Q150</sup> mice and the overall size and appearance of the islets were similar to that of the controls (<xref ref-type="fig" rid="pone-0008025-g003">Figure 3B</xref>). Inclusions have been reported in the &#x003b1;-cells and &#x003b4;-cells of the R6/2 islets <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist2">&#x0005b;25&#x0005d;</xref> but without specialised staining procedures it was not possible to determine if the other islet cell types also contained inclusions in the knock-in model. A very small number of acinar cells of the exocrine pancreas were found to have nuclear inclusions and we noted inclusions in some cells of the connective tissue. The distribution of inclusions was similar in both animal models but the islet cells of R6/2 were smaller and more heavily stained. We also observed inclusions in epithelial cells of a pancreatic duct in R6/2, but did not find any ducts in the <italic>Hdh</italic><sup>Q150/Q150</sup> sections examined for comparison. We examined the ultrastructure appearance of the pancreatic islets of the <italic>Hdh</italic><sup>Q150/Q150</sup> mice (<xref ref-type="fig" rid="pone-0008025-g003">Figure 3C</xref>) and found no obvious differences at the ultrastructural level when compared to control animals (<xref ref-type="fig" rid="pone-0008025-g003">Figure 3D</xref>). This is in contrast to the previously described ultrastructure of the islets in R6/2 mice <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist2">&#x0005b;25&#x0005d;</xref>, in which there was a depletion in the numbers of &#x003b2;-granules in the &#x003b2;-cells and a reduction in the numbers of &#x003b2;-cells with a resultant reduction in the size of the islets, a result that we confirmed in this study (<xref ref-type="fig" rid="pone-0008025-g003">Figure 3E</xref>). The &#x003b2;-cells were small with fewer granules and organelles and the cytoplasm was denser than normal, suggestive of cell atrophy. The &#x003b1;-cells and &#x003b4;-cells appeared relatively normal.</p></sec><sec id="s2d"><title>Inclusion pathology is present throughout the stomach wall</title><p>We used transverse sections of the stomach wall of the <italic>Hdh</italic><sup>Q150/Q150</sup> mice to investigate inclusion distribution in the fundus, corpus and pyloric regions of the stomach (<xref ref-type="fig" rid="pone-0008025-g004">Figure 4</xref>). Inclusion distribution was similar in all three regions. As in other tissues the distribution of inclusions was not uniform but patchy. In the gastric glands, small inclusions were found in the connective tissue and in the mucosal cells of the gland neck (<xref ref-type="fig" rid="pone-0008025-g004">Figure 4B</xref>). Larger inclusions were found in the epithelial cells at the gland base (<xref ref-type="fig" rid="pone-0008025-g004">Figure 4C</xref>), but specialised staining would be needed to establish the specific cell type involved: parietal, APUD or chief cells. They were also observed in connective tissue cells in the interstitium and adventitia of large blood vessels of the submucosa. There were large nuclear inclusions in the ganglionic neurons of the submucosal plexus (Meissner's) (<xref ref-type="fig" rid="pone-0008025-g004">Figure 4D</xref>) and in the ganglion neurons of the myenteric (Auerbach's) plexus (<xref ref-type="fig" rid="pone-0008025-g004">Figure 4F</xref>). We also noted nuclear inclusions in the neurons of a third group of ganglia, on the outer surface of the muscularis externa located mostly over the corpus region of the stomach, the serosal ganglia (<xref ref-type="fig" rid="pone-0008025-g004">Figure 4G</xref>) <xref ref-type="bibr" rid="pone.0008025-Powley1">&#x0005b;26&#x0005d;</xref>. Nuclear inclusions were also observed in small groups of smooth muscle cells throughout the muscularis externa (<xref ref-type="fig" rid="pone-0008025-g004">Figure 4E</xref>). A similar distribution of inclusions was found in the R6/2 mouse model.</p><p>In the duodenum inclusions were observed in the ganglion cells of the myenteric and submucosal plexi and the interstitial connective tissue in both mouse models (data not shown). A similar distribution was seen in the rectum and we also observed a small number of smooth muscle cells with inclusions in the muscularis externa (data not shown). The ileum, jejunum, caecum and colon were not available for analysis.</p></sec><sec id="s2e"><title>Inclusion pathology is comparable in the male and female reproductive organs of both the <italic>Hdh</italic>Q150 and R6/2 mouse models</title><p>The male reproductive organs of <italic>Hdh</italic><sup>Q150/Q150</sup> mice contained a few cells in the testicular epithelium of the seminiferous tubules of the testis that had nuclear inclusions, the identity of which needs to be confirmed by appropriate histological staining. Inclusions were also noted in the peritubular contractile cells of the tunica propria. An examination of the seminal vesicles (<xref ref-type="fig" rid="pone-0008025-g005">Figure 5A</xref>) from both mouse models revealed the presence of inclusions in the glandular epithelial cells. Inclusions were also found in the glandular epithelial cells of the coagulation gland (dorsocranial part of the prostate gland) (<xref ref-type="fig" rid="pone-0008025-g005">Figure 5B</xref>) in both models. In females, inclusions were only found in the connective tissue of the oviduct and the ovarial capsule (tunica albuginea) and interstitium in both mouse models (data not shown)</p></sec><sec id="s2f"><title>Selective inclusion pathology in adipose tissue</title><p>To investigate brown fat we examined the sub-clavical fat pads. A small number of the adipocyte nuclei were found to contain inclusions in <italic>Hdh</italic><sup>Q150/Q150</sup> mice, larger numbers of inclusions were found in the R6/2 model. We examined the visceral fat pads and found no inclusions in white fat adipocytes in either mouse model (data not shown).</p></sec><sec id="s2g"><title>Inclusion negative tissues</title><p>In addition to the ovaries and white fat already mentioned, inclusions were not present in any of the layers of the skin or principle cell types of the spleen in either mouse model. However, we observed small numbers of nuclear inclusions in connective tissue cells in the <italic>Hdh</italic><sup>Q150/Q150</sup> and R6/2 mice in all tissues examined, including the fibroblasts of the adventitia of larger blood vessels. Even the tissues and organs in which the principle cell types did not contain inclusions, the connective tissue cells did, for example the myofibroblasts of the capsule and trabeculae in spleen (<xref ref-type="fig" rid="pone-0008025-g005">Figure 5C</xref>) and fibroblasts in subcutaneous connective tissue of the skin.</p></sec><sec id="s2h"><title>Shrinkage/atrophy of organs in the <italic>Hdh</italic>Q150 knock-in mouse model</title><p>Symptomatic HD patients exhibit pronounced weight loss and muscle atrophy <xref ref-type="bibr" rid="pone.0008025-Djousse1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Sanberg1">&#x0005b;27&#x0005d;</xref>, phenotypes that are modelled in both the R6/2 and <italic>Hdh</italic>Q150 mouse models of HD <xref ref-type="bibr" rid="pone.0008025-Mangiarini1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Woodman1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Davies1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Hockly1">&#x0005b;29&#x0005d;</xref>. Failure to gain weight begins at approximately 7 weeks of age in R6/2 males and 11 weeks in R6/2 females <xref ref-type="bibr" rid="pone.0008025-Davies1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Hockly1">&#x0005b;29&#x0005d;</xref> whereas, both male and female <italic>Hdh</italic><sup>Q150/Q150</sup> mice stop gaining weight at approximately 9 months of age <xref ref-type="bibr" rid="pone.0008025-Woodman1">&#x0005b;13&#x0005d;</xref>. We have previously determined the extent of organ atrophy <xref ref-type="bibr" rid="pone.0008025-Sathasivam1">&#x0005b;15&#x0005d;</xref> in 12 week old symptomatic R6/2 mice for the heart, liver, kidneys, testes and skeletal muscle. In order to determine whether organ atrophy had also occurred in the knock-in model, we compared the weights of heart, kidney, quadriceps, spleen, liver and testes from four 22 month old <italic>Hdh</italic><sup>Q150/Q150</sup> mice to those of four wild type littermates (two male and two female in each case) (<xref ref-type="table" rid="pone-0008025-t002">Table 2</xref>). In all cases, the mean organ weight was lower in the <italic>Hdh</italic><sup>Q150/Q150</sup> mice than in their wild type littermates. The difference in these values was highly statistically significant for quadriceps, kidney and testes but did not reach statistical significance for heart, liver and spleen. At least for liver and heart, this is most likely due to the small number of animals studied.</p><table-wrap id="pone-0008025-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008025.t002</object-id><label>Table 2</label><caption><title>Extent of organ atrophy in the <italic>Hdh</italic><sup>Q150/Q150</sup> mice at 22 months of age.</title></caption><alternatives><graphic id="pone-0008025-t002-2" xlink:href="pone.0008025.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Mean Weight g (&#x000b1;Std. Error)</td><td align="left" rowspan="1" colspan="1">Independent samples <italic>t</italic>-test</td><td align="left" rowspan="1" colspan="1">&#x00025; Weight of WT</td><td align="left" rowspan="1" colspan="1">&#x00025; Weight of WT</td></tr><tr><td align="left" rowspan="1" colspan="1">Organ/Tissue</td><td align="left" rowspan="1" colspan="1">WT 22 month</td><td align="left" rowspan="1" colspan="1"><italic>Hdh</italic><sup>Q150/Q150</sup> 22 month</td><td align="left" rowspan="1" colspan="1">2-tailed p values</td><td align="left" rowspan="1" colspan="1"><italic>Hdh</italic><sup>Q150/Q150</sup> 22 month</td><td align="left" rowspan="1" colspan="1">R6/2 12 wk previous study <xref ref-type="bibr" rid="pone.0008025-Sathasivam1">&#x0005b;15&#x0005d;</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Quadriceps muscle</td><td align="left" rowspan="1" colspan="1">0.17&#x000b1;0.01</td><td align="left" rowspan="1" colspan="1">0.09&#x000b1;0.01</td><td align="left" rowspan="1" colspan="1">p&#x0003c;0.001 <xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">42</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart</td><td align="left" rowspan="1" colspan="1">0.18&#x000b1;0.03</td><td align="left" rowspan="1" colspan="1">0.12&#x000b1;0.01</td><td align="left" rowspan="1" colspan="1">p&#x0200a;&#x0003d;&#x0200a;0.152</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver</td><td align="left" rowspan="1" colspan="1">1.41&#x000b1;0.12</td><td align="left" rowspan="1" colspan="1">1.19&#x000b1;0.06</td><td align="left" rowspan="1" colspan="1">p&#x0200a;&#x0003d;&#x0200a;0.212</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">75</td></tr><tr><td align="left" rowspan="1" colspan="1">Kidney</td><td align="left" rowspan="1" colspan="1">0.22&#x000b1;0.02</td><td align="left" rowspan="1" colspan="1">0.17&#x000b1;0.02</td><td align="left" rowspan="1" colspan="1">p&#x0200a;&#x0003d;&#x0200a;0.031 <xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">Spleen</td><td align="left" rowspan="1" colspan="1">0.10&#x000b1;0.00</td><td align="left" rowspan="1" colspan="1">0.09&#x000b1;0.03</td><td align="left" rowspan="1" colspan="1">p&#x0200a;&#x0003d;&#x0200a;0.391</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">67</td></tr><tr><td align="left" rowspan="1" colspan="1">Testes</td><td align="left" rowspan="1" colspan="1">0.08&#x000b1;0.01</td><td align="left" rowspan="1" colspan="1">0.03&#x000b1;0.01</td><td align="left" rowspan="1" colspan="1">p&#x0200a;&#x0003d;&#x0200a;0.005 <xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">15</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>Organs were removed from perfusion fixed 22 month old <italic>Hdh</italic><sup>Q150/Q150</sup> mice and their wild type littermate controls (n&#x0200a;&#x0003d;&#x0200a;4 mice/genotype) and weighed to determine the extent of organ atrophy. These data are compared to those previously calculated for R6/2 mice at 12 weeks of age as compared to wild type littermates.</p></fn><fn id="nt103"><label>&#x0002a;</label><p>statistically significant.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2i"><title>Investigation of muscle fibre morphology</title><p>We had previously conducted a relatively detailed analysis of muscle pathology in the R6/2 mouse and had identified a uniform reduction in the muscle fibre diameter of the quadriceps muscles <xref ref-type="bibr" rid="pone.0008025-Sathasivam1">&#x0005b;15&#x0005d;</xref>. To investigate whether this is also a feature of <italic>Hdh</italic><sup>Q150/Q150</sup> muscles, we measure the bound width (shortest) of all fibres in 10 random micrographs from transverse quadriceps sections stained with H&#x00026;E from each mouse. The fibre diameters for each genotype were pooled <italic>Hdh</italic><sup>Q150/Q150</sup>, n&#x0200a;&#x0003d;&#x0200a;881; wild type, n&#x0200a;&#x0003d;&#x0200a;450. The mean diameters (&#x000b1;SE) were wild type, 44.36&#x000b1;14.46 and <italic>Hdh</italic><sup>Q150/Q150</sup>, 35.16&#x000b1;12.2 (p&#x0003c;0.001). The same micrographs were also examined for the percentage of fibres with central nuclei, the number of small angular fibres (<xref ref-type="table" rid="pone-0008025-t003">Table 3</xref>) and the presence of split fibres. There were 10&#x00025; central nuclei in the 22 month old <italic>Hdh</italic><sup>Q150/Q150</sup> mice, which is greater than the normal value (&#x02264;3&#x00025;) and a possible indicator of muscle myopathy <xref ref-type="bibr" rid="pone.0008025-Sewry1">&#x0005b;30&#x0005d;</xref> and split fibres were also present. The percentage of angular fibres was within the normal range and no other evidence for neuropathy was found.</p><table-wrap id="pone-0008025-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008025.t003</object-id><label>Table 3</label><caption><title>Analysis of indicators of myopathy and neuropathy in skeletal muscle.</title></caption><alternatives><graphic id="pone-0008025-t003-3" xlink:href="pone.0008025.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No. Fibres</td><td align="left" rowspan="1" colspan="1">No. Fibres Central Nuclei</td><td align="left" rowspan="1" colspan="1">&#x00025; Fibres Central Nuclei</td><td align="left" rowspan="1" colspan="1">Total Angular Fibres</td><td align="left" rowspan="1" colspan="1">&#x00025; Angular Fibres</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">459</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Hdh</italic><sup>Q150/Q150</sup></td><td align="left" rowspan="1" colspan="1">916</td><td align="left" rowspan="1" colspan="1">99</td><td align="left" rowspan="1" colspan="1">10.81</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0.54</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>Greater than 3&#x00025; of central nuclei is considered abnormal and a possible indicator of muscle myopathy in humans. Based on these criteria, there is evidence for myopathy in the <italic>Hdh</italic><sup>Q150/Q150</sup> mice. The percentage of angular fibres is within the normal range.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3"><title>Discussion</title><p>Although HD is a neurodegenerative disorder, the <italic>HD</italic> gene is ubiquitously expressed, and whilst it is understandable that HD research is predominantly focussed on the central nervous system (CNS), evidence is accumulating to suggest that some HD symptoms may be caused by a peripheral pathology. The mechanistic role that polyQ inclusions play in the pathogenesis of HD remains the subject of much debate, however, their presence is considered to be indicative of pathology. In this study, we have shown that the distribution of nuclear inclusions in the peripheral tissues of the R6/2 and <italic>Hdh</italic>Q150 models is almost identical at end-stage disease and therefore, the peripheral pathology of these two HD mouse models is highly comparable. Peripheral pathology was identified in skeletal muscle, heart, pancreas, adrenal gland, liver, kidney, the gastrointestinal (GI) tract, brown fat, male reproductive organs and connective tissue. In most cases, the cell types that are affected are, like neurons, terminally differentiated. Additional factors that might influence the propensity to form inclusions in a particular cell type could include expression level of the R6/2 transcript or <italic>Hdh</italic> gene, Htt proteolysis and protein folding and clearance networks. Organ atrophy was also a feature of both models with the testes exhibiting the most dramatic weight loss followed by skeletal muscle in both cases.</p><p>Therefore, we have demonstrated that the peripheral pathology documented in the R6/2 mice is not the result of the aberrant expression of a small N-terminal fragment of mutant Htt as it is also present in a genetically precise HD mouse model in which an expanded CAG repeat has been inserted into the mouse <italic>Hdh</italic> gene. This peripheral pathology may be responsible for some of the phenotypes exhibited by the two mouse models. The nuclear inclusions that form in brain have recruited many additional nuclear and cytoplasmic proteins and a detailed analysis of the proteins that are recruited into inclusions in any one of the peripheral tissues may shed light on the pathogenic processes. Whether peripheral pathology has relevance to the human disease is under investigation but, in general, has yet to be established.</p><p>Skeletal muscle atrophy is observed in many HD patients despite an adequate diet and food intake <xref ref-type="bibr" rid="pone.0008025-Sanberg1">&#x0005b;27&#x0005d;</xref>, significant body weight changes are measurable in early as well as late stage disease <xref ref-type="bibr" rid="pone.0008025-Djousse1">&#x0005b;17&#x0005d;</xref> and weight loss has recently been shown to track with CAG repeat length <xref ref-type="bibr" rid="pone.0008025-Aziz1">&#x0005b;18&#x0005d;</xref>. The use of a hand-held dynamometer has recently shown that people with HD have a significant reduction in lower limb muscle strength to, on average, about half of the strength of healthy matched controls <xref ref-type="bibr" rid="pone.0008025-Busse1">&#x0005b;20&#x0005d;</xref>. The presence of dense granular deposits, immunoreactive to an anti-huntingtin antibody, have been found in the muscle of an HD patient, but were absent from a control sample <xref ref-type="bibr" rid="pone.0008025-Saft1">&#x0005b;31&#x0005d;</xref>. Might the pathogenic mechanism that underlies these symptoms be intrinsic to muscle pathology? We have previously shown that nuclear inclusions form in the muscle fibres of R6/2 mice <xref ref-type="bibr" rid="pone.0008025-Sathasivam1">&#x0005b;15&#x0005d;</xref> and that the loss of muscle bulk in both the R6/2 and R6/1 mice is associated with pronounced muscle fibre atrophy. Perturbations in the R6/2 hypothalamic-pituitary-adrenal axis suggest that the R6/2 mice develop a Cushing-like syndrome <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist1">&#x0005b;24&#x0005d;</xref> due to increased glucocorticoid levels, however, we did not observe the selective type 2 (fast) fibre type atrophy that this would predict, instead a pronounced uniform atrophy had occurred. A detailed study by Ribchester et al. also found no evidence for a myopathy (myofibre necrosis, myophagocytosis, regeneration, rounded atrophic fibres, fibre hypertrophy and splitting, centralized nuclei, fibrosis ring fibres, vacuoles or any sign of inflammation) <xref ref-type="bibr" rid="pone.0008025-Ribchester1">&#x0005b;32&#x0005d;</xref> or for a denervation-like pathology (angulated atrophic fibres, fibre-type grouping, group atrophy or target fibres), discounting neuropathic causes until end-stage disease. Instead, they identified a complex phenotype with R6/2 muscle fibres undergo profound atrophy with many showing membrane characteristics of denervated or paralysed muscle fibres <xref ref-type="bibr" rid="pone.0008025-Ribchester1">&#x0005b;32&#x0005d;</xref>. We have shown that the muscle fibres of the <italic>Hdh</italic>Q150 knock-in model, like those of the R6/2 mice contain nuclear inclusions. The evidence for myopathy in <italic>Hdh</italic><sup>Q150/Q150</sup> mice was greater than in R6/2 as there was a higher frequency of central nuclei and some split fibres. In support of a mechanism intrinsic to muscle, a semi professional marathon runner at risk for HD developed signs of a slowly progressive myopathy with exercise-induced muscle fatigue, pain, elevated creatine kinase level and worsening of his running performance many years before the first signs of chorea were detected <xref ref-type="bibr" rid="pone.0008025-Kosinski1">&#x0005b;33&#x0005d;</xref>. Common gene expression profiles in skeletal muscle between R6/2 mice, <italic>Hdh</italic><sup>Q150/Q150</sup> mice and HD patients have previously been reported to reflect disease progression and be consistent with the beginnings of a transition from fast-twitch to slow twitch muscle fibre types <xref ref-type="bibr" rid="pone.0008025-Strand1">&#x0005b;34&#x0005d;</xref>. More recently, impaired activity of PPAR&#x003b3; coactivator 1&#x003b1; (PGC-1&#x003b1;) and its target genes, important for inducing mitochondrial biogenesis and in influencing whether muscle contains slow twitch oxidative or fast twitch glycolytic fibres, has been demonstrated in the muscle and myoblasts of HD patients and the muscle of N171-82Q mice <xref ref-type="bibr" rid="pone.0008025-Chaturvedi1">&#x0005b;35&#x0005d;</xref>. However, there is also evidence to suggest that the reduction in muscle bulk can occur by through pathogenic events exogenous to muscle that are either peripherally or centrally generated. The metabolic profile of plasma from both N171-82Q mice and HD patients supports a reduction in muscle bulk being caused by a catabolic state secondary to hypothalamic pathology <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Goodman1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-vanderBurg1">&#x0005b;37&#x0005d;</xref> which is known to occur in both mouse models of HD and HD patients <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Petersen1">&#x0005b;38&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Aziz2">&#x0005b;39&#x0005d;</xref>. In addition, increased plasma cytokine levels, notably IL6 and TNF&#x003b1;, have been detected in people who carry the HD mutation 16 years before the predicted onset of motor symptoms <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist3">&#x0005b;40&#x0005d;</xref> and could contribute to muscle wasting.</p><p>Early-onset cardiovasclular disease is the second leading cause of death in HD patients <xref ref-type="bibr" rid="pone.0008025-Lanska1">&#x0005b;41&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Sorensen1">&#x0005b;42&#x0005d;</xref>. The inclusion pathology in the hearts of both the R6/2 and <italic>Hdh</italic>Q150 models was comparatively sparse although cardiac dysfunction has been described in R6/2 mice <xref ref-type="bibr" rid="pone.0008025-Mihm1">&#x0005b;43&#x0005d;</xref>. The formation of polyQ amyloid has been shown to cause heart failure as transgenic mice that express an 83 residue long polyQ repeat in cardiomyocytes exhibited reduced cardiac function and dilation by five months and all died by eight months <xref ref-type="bibr" rid="pone.0008025-Pattison1">&#x0005b;44&#x0005d;</xref>. An electrolyte imbalance has been described in the R6/2 mice at 12 weeks of age <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist1">&#x0005b;24&#x0005d;</xref> which could exacerbate cardiac failure. A detailed analysis of cardiac function in the <italic>Hdh</italic>Q150 knock-in model and in HD patients is warranted.</p><p>Pancreatic inclusion pathology has been reported in all of the N-terminal Htt transgenic HD models: R6/2 mice <xref ref-type="bibr" rid="pone.0008025-Sathasivam1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist2">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Hunt1">&#x0005b;45&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Andreassen1">&#x0005b;46&#x0005d;</xref>, R6/1 mice (which express the same exon 1 transgene but at a lower level) <xref ref-type="bibr" rid="pone.0008025-Josefsen1">&#x0005b;47&#x0005d;</xref> and N171-82Q mice <xref ref-type="bibr" rid="pone.0008025-Martin1">&#x0005b;16&#x0005d;</xref> and the presence of aggregates has been shown to correlate with islet size <xref ref-type="bibr" rid="pone.0008025-Martin1">&#x0005b;16&#x0005d;</xref>. A subset of R6/2 mice develop diabetes, and all R6/2 mice have impaired glucose homeostasis <xref ref-type="bibr" rid="pone.0008025-Hunt1">&#x0005b;45&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Andreassen1">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Hurlbert1">&#x0005b;48&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Luesse1">&#x0005b;49&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Fain1">&#x0005b;50&#x0005d;</xref>, a phenotype that has also been reported in the R6/1 <xref ref-type="bibr" rid="pone.0008025-Josefsen1">&#x0005b;47&#x0005d;</xref>, N171-82Q <xref ref-type="bibr" rid="pone.0008025-Martin1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Duan1">&#x0005b;51&#x0005d;</xref> and <italic>Hdh</italic>Q150 knock-in models <xref ref-type="bibr" rid="pone.0008025-Strand1">&#x0005b;34&#x0005d;</xref>. The pancreatic islets of the R6/2 mice have been shown to express reduced levels of the islet hormones: insulin, somatostatin and glucagon <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist2">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Andreassen1">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Hurlbert1">&#x0005b;48&#x0005d;</xref> and exhibit intrinsic deficits in insulin production <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist2">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Andreassen1">&#x0005b;46&#x0005d;</xref>. R6/2 mice develop an age-dependent reduction in insulin mRNA production and diminished expression of key regulators of insulin gene transcription: PDX-1, E2A, CBP, and p300 <xref ref-type="bibr" rid="pone.0008025-Andreassen1">&#x0005b;46&#x0005d;</xref>. This is paralleled by a decrease in &#x003b2;-cell mass (possibly caused through a decrease in &#x003b2;-cell replication), an absence of exocytosis as induced by membrane depolarization and a dramatic reduction in the number of secretory vesicles in R6/2 &#x003b2;-cells <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist2">&#x0005b;25&#x0005d;</xref>. A decrease in &#x003b2;-cell mass has also been described in R6/1 <xref ref-type="bibr" rid="pone.0008025-Josefsen1">&#x0005b;47&#x0005d;</xref> and N171-82Q mice <xref ref-type="bibr" rid="pone.0008025-Martin1">&#x0005b;16&#x0005d;</xref>. Further support for the diabetes in the R6/2 mice being caused by impairment in insulin release rather than insulin insensitivity has been generated by the administration of pharmacological agents <xref ref-type="bibr" rid="pone.0008025-Hunt1">&#x0005b;45&#x0005d;</xref>. In this study, we have shown that inclusions are present in the pancreatic islet cells of <italic>Hdh</italic><sup>Q150/Q150</sup> mice which combined with previous reports of impaired glucose homeostasis in this model, suggests that the pancreatic pathology described in the N-terminal fragment models extends to the HD knock-in models. However, the inclusion pathology exhibited greater variation between <italic>Hdh</italic><sup>Q150/Q150</sup> mice than in R6/2 and we did not find a reduction in the number of secretory vesicles in knock-in &#x003b2;-cells. The extent to which these findings extend to HD patients currently remains unclear. Impairment in insulin secretion capacity and a simultaneous decrease in insulin sensitivity, with an increase in the insulin resistance level was recently reported in normoglycaemic HD patients <xref ref-type="bibr" rid="pone.0008025-Lalic1">&#x0005b;21&#x0005d;</xref>. However, in a different study, the level of insulin transcripts as measured by immunostaining and the islet &#x003b2;-cell area were similar in HD patients and controls. Pancreatic islets appeared histologically normal and there was no sign of amyloid deposition <xref ref-type="bibr" rid="pone.0008025-Bacos1">&#x0005b;52&#x0005d;</xref>.</p><p>Many of the peripheral symptoms that have been described in HD patients and mouse models of HD could be the result of disturbed hypothalamic-endocrine axes <xref ref-type="bibr" rid="pone.0008025-Petersen2">&#x0005b;53&#x0005d;</xref>. As mentioned above, disturbances in the hypothalamic-pituitary-adrenal axis could contribute to weight loss and there is marked adrenal pathology in both the R6/2 and <italic>Hdh</italic><sup>Q150/Q150</sup> mice. The hypertrophy of the adrenal cortex and progressive increase in corticosterone levels could account for reduced bone mineral density, insulin resistance and muscular atrophy recorded in R6/2 mice <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist1">&#x0005b;24&#x0005d;</xref>. Increased levels of corticosteroids have been reported in HD patients <xref ref-type="bibr" rid="pone.0008025-Bjorkqvist1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Petersen2">&#x0005b;53&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Saleh1">&#x0005b;54&#x0005d;</xref>, but a recent study dissociated this from weight loss <xref ref-type="bibr" rid="pone.0008025-Saleh1">&#x0005b;54&#x0005d;</xref>. Impairments were<xref ref-type="bibr" rid="pone.0008025-Saleh1">&#x0005b;54&#x0005d;</xref> identified in several anterior pituitary axes <xref ref-type="bibr" rid="pone.0008025-Saleh1">&#x0005b;54&#x0005d;</xref>. Both central growth hormone (GH) and peripheral insulin growth factor-1 (IGF-1) somatotropic hormones were higher in HD patients, increased with disease progression and were linked to weight loss, potentially implicating a liver pathology. Testicular pathology has been described in HD patients with reduced numbers of germ cells and abnormal seminiferous tubule morphology <xref ref-type="bibr" rid="pone.0008025-VanRaamsdonk1">&#x0005b;55&#x0005d;</xref>. We have shown that the testes are reduced in size in both R6/2 and <italic>Hdh</italic><sup>Q150/Q150</sup> mice, also reported in the YAC128 HD mouse model <xref ref-type="bibr" rid="pone.0008025-VanRaamsdonk1">&#x0005b;55&#x0005d;</xref>, and testosterone levels are reduced in both R6/2 mice <xref ref-type="bibr" rid="pone.0008025-Papalexi1">&#x0005b;56&#x0005d;</xref> and male HD patients <xref ref-type="bibr" rid="pone.0008025-Saleh1">&#x0005b;54&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Markianos1">&#x0005b;57&#x0005d;</xref>. This could arise through a decrease in the production of gonadotrophin-releasing hormone in the hypothalamus <xref ref-type="bibr" rid="pone.0008025-Papalexi1">&#x0005b;56&#x0005d;</xref>, a loss of the direct neuronal hypothalamic-testicular pathway <xref ref-type="bibr" rid="pone.0008025-Saleh1">&#x0005b;54&#x0005d;</xref> or the direct effect of mutant Htt in the testes <xref ref-type="bibr" rid="pone.0008025-VanRaamsdonk1">&#x0005b;55&#x0005d;</xref>.</p><p>Body weight regulation is a highly complex process that involves the GI tract and adipose tissue in addition to the hypothalamus and pancreas discussed above <xref ref-type="bibr" rid="pone.0008025-vanderBurg1">&#x0005b;37&#x0005d;</xref>. It is governed by the balance of food intake, energy expenditure and metabolism. Both the R6/2 mice and HD patients have been shown to have an increased metabolic rate <xref ref-type="bibr" rid="pone.0008025-Goodman1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-vanderBurg1">&#x0005b;37&#x0005d;</xref>. The hypothalamus integrates peripheral signals of energy levels and regulates food intake, energy balance and metabolism. Van der Burg et al. <xref ref-type="bibr" rid="pone.0008025-vanderBurg1">&#x0005b;37&#x0005d;</xref> have shown that there are reduced levels of hypothalamic peptides important for regulating food intake and metabolism. We have demonstrated that inclusions are present in the adipocytes of R6/2 and <italic>Hdh</italic><sup>Q150/Q150</sup> mice, a pathology also present in N171-82Q mice <xref ref-type="bibr" rid="pone.0008025-Weydt1">&#x0005b;58&#x0005d;</xref>. Adipose tissue-derived hormones that regulate food intake and glucose metabolism have been shown to be dysregulated in the R6/2 <xref ref-type="bibr" rid="pone.0008025-Fain1">&#x0005b;50&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Phan1">&#x0005b;59&#x0005d;</xref> and <italic>Hdh</italic>Q140 knock-in HD models <xref ref-type="bibr" rid="pone.0008025-Phan1">&#x0005b;59&#x0005d;</xref>, suggesting an intrinsic adipocyte dysfunction that may contribute to weight loss. Mutant Htt has been shown to dysregulate gene expression in adipocytes, including PGC-1&#x003b1; and its target genes including the uncoupling proteins (UCPs) <xref ref-type="bibr" rid="pone.0008025-vanderBurg1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Weydt1">&#x0005b;58&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Phan1">&#x0005b;59&#x0005d;</xref> resulting in impaired thermogenesis and metabolic abnormalities. As mentioned above, PGC-1&#x003b1; activity is also decreased in muscle from HD patients and N171-82Q mice <xref ref-type="bibr" rid="pone.0008025-Chaturvedi1">&#x0005b;35&#x0005d;</xref> and given the pathology that we have described in R6/2 and <italic>Hdh</italic><sup>Q150/Q150</sup> liver, an investigation of the UCPs in liver is warranted. We identified inclusion pathology throughout the stomach wall and in the plexi of the stomach, duodenum and rectum. Grehlin, a peptide produced in the gastric mucosa that stimulates food intake has been shown to be down-regulated in the R6/2 mice <xref ref-type="bibr" rid="pone.0008025-vanderBurg1">&#x0005b;37&#x0005d;</xref> implicating a direct role for the GI tract in HD pathology.</p><p>As peripheral tissues are more accessible than those of the CNS, the presence of peripheral HD pathologies might lead to biomarkers that can be used to track disease progression in therapeutic intervention trials. Whether peripheral clinical biomarkers for adult onset HD can be identified will depend on the analysis of patient samples. It is unlikely that inclusion formation in the peripheral tissues of the <italic>Hdh</italic>Q150 knock-in mice will provide a useful read-out in preclinical studies as our preliminary analyses suggest that aggregate formation in the periphery occurs later than that in brain <xref ref-type="bibr" rid="pone.0008025-Sathasivam2">&#x0005b;60&#x0005d;</xref>. However, the peripheral pathologies in the R6/2 model allow proof of concept studies with potentially disease modifying therapeutic compounds to be performed without the initial requirement to cross the blood brain barrier.</p><p>We have identified extensive inclusion pathology with a very similar distribution in two quite different mouse models of HD. There is mounting evidence to indicate that peripheral pathologies contribute to phenotypes exhibited by these and other HD mouse models alongside effects from the CNS. The size of the CAG repeat expansion in both the R6/2 and <italic>Hdh</italic>Q150 models is of a size that would cause childhood disease in humans and would be expected to result in a more widespread pathology than CAG repeat expansions in the adult onset range. Therefore, although many peripheral symptoms of adult onset HD have been documented, the extent to which the peripheral pathology identified in the mouse models relates to adult onset disease is as yet unknown. There have been very few studies of the peripheral pathology in HD organs, largely because <italic>post mortem</italic> specimens have not been available for analysis. However, it is very important that a comprehensive analysis of HD peripheral pathology is undertaken, both to allow a better mechanistic understanding of the disease and to inform possible therapeutic interventions that might alleviate some HD symptoms by targeting dysfunction in peripheral organs.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and Methods</title><sec id="s4a"><title>Ethics statement</title><p>All animal work was approved by the King's College London Ethical Review Panel and performed under Home Office project and personal licenses.</p></sec><sec id="s4b"><title>HD mouse models</title><p>Hemizygous R6/2 mice <xref ref-type="bibr" rid="pone.0008025-Mangiarini1">&#x0005b;10&#x0005d;</xref> were bred by backcrossing R6/2 males to (CBA x C57Bl/6) F1 females (B6CBAF1/OlaHsd, Harlan Olac, Bicester, UK). <italic>Hdh</italic><sup>Q150/Q150</sup> homozygous knock-in mice <xref ref-type="bibr" rid="pone.0008025-Lin1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008025-Woodman1">&#x0005b;13&#x0005d;</xref> on a (CBA x C57Bl/6) F1 background were generated by intercrossing <italic>Hdh</italic><sup>Q150/Q7</sup> heterozygous CBA/Ca and C57BL/6J congenic lines (inbred lines from Harlan Olac, Bicester, UK). All animals were subject to a 12 h light/dark cycle, had unlimited access to water and breeding chow (Special Diet Services, Witham, UK). Housing conditions and environmental enrichment were as previously described <xref ref-type="bibr" rid="pone.0008025-Hockly1">&#x0005b;29&#x0005d;</xref>. R6/2 mice were always housed with wild type mice. The CAG repeat size in the R6/2 mouse was 213 and in the <italic>Hdh</italic><sup>Q150/Q150</sup> mice was 155&#x000b1;3.4 (SD).</p></sec><sec id="s4c"><title>Genotyping and CAG repeat sizing</title><p>R6/2 and <italic>Hdh</italic><sup>Q150/Q150</sup> mice were identified by PCR of tail-tip DNA. For R6/2, a 10 &#x000b5;l reaction contained 100 ng DNA, 1x Thermo-Start master mix (Thermo Scientific), 1 &#x000b5;l DMSO, 10 ng/&#x000b5;l forward primer 33727 &#x0005b;<named-content content-type="gene">5&#x02032;-CGCAGGCTAGGGCTGTCAATCATGCT-3&#x02032;</named-content>&#x0005d;, and 10 ng/&#x000b5;l reverse primer 32252 &#x0005b;<named-content content-type="gene">5&#x02032;-TCATCAGCTTTTCCAGGGTCGCCAT-3&#x02032;</named-content>&#x0005d;. Cycling conditions were: 15 min @ 94&#x000b0;C, 35&#x000d7;(30 s @ 94&#x000b0;C; 30 s @ 60&#x000b0;C, 60 s @72&#x000b0;C) and 10 min @ 72&#x000b0;C. The amplified R6/2 transgene product was 272 bp. For <italic>Hdh</italic><sup>Q150/Q150</sup> mice, a 20 &#x000b5;l reaction contained 150 ng tail-tip DNA, 0.1 mM dNTPs, 2 M betaine (Sigma), 1x Detloff buffer &#x0005b;15 mM Tris&#x02013;HCl (pH 8.8), 15 mM Tris&#x02013;HCl (pH 9.0), 16 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2.5 mM MgCl<sub>2</sub>, 0.15 mg/ml bovine serum albumin (BSA), 0.007&#x00025; &#x003b2;-mercaptoethanol&#x0005d;, 10 ng/&#x000b5;l forward primer MHD16 &#x0005b;<named-content content-type="gene">5&#x02032;-CCCATTCATTGCCTTGCTGCTAGG-3&#x02032;</named-content>&#x0005d;, 10 ng/&#x000b5;l reverse primer MHD18 &#x0005b;<named-content content-type="gene">5&#x02032;-GACTCACGGTCGGTGCAGCGGTTCC-3&#x02032;</named-content>&#x0005d;, and 1 U Herculase Taq polymerase (Stratagene). Amplification conditions were: 5 min @ 95&#x000b0;C, 30&#x000d7;(30 s @ 94&#x000b0;C, 30 s @ 58&#x000b0;C, 3 min @ 72&#x000b0;C) and 5 min @ 72&#x000b0;C. The wild type allele amplified a 278 bp product whereas the <italic>Hdh</italic>Q150 knock-in allele amplified a 707 bp product. Amplification of the CAG repeat from R6/2 mouse DNA was performed with a FAM labelled forward primer (<named-content content-type="gene">GAGTCCCTCAAGTCCTTCCAGCA</named-content>) and reverse primer (<named-content content-type="gene">GCCCAAACTCACGGTCGGT</named-content>) in 10 &#x000b5;l reactions containing: 0.2 mM dNTPs; 10&#x00025; DMSO; AM buffer (67 mM Tris-HCL pH 8.8; 16.6 mM (NH<sub>4</sub>)S0<sub>4</sub>; 2 mM MgCl<sub>2</sub>; 0.17 mg/ml BSA) and 0.5U AmpliTaq DNA polymerase (Applied Biosystems). Cycling conditions were: 90 s @ 94&#x000b0;C, 24&#x000d7;(30 s @ 94&#x000b0;C; 30 s @ 65&#x000b0;C; 90 s @ 72&#x000b0;C) and 10 min @ 72&#x000b0;C. For <italic>Hdh</italic><sup>Q150/Q150</sup> mice, the amplification reaction was as for genotyping (above) with a FAM labelled reverse MHD18 primer. All instruments and materials were obtained from Applied Biosystems unless indicated. The FAM-tagged PCR product (1 &#x000b5;l) together with MegaBACE<sup>TM</sup> ET900 (Amersham Bioscience) internal size standard (0.04 &#x000b5;l) were denatured at 94&#x000b0;C, 5 min in 9 &#x000b5;l of HiDi-formamide and analyzed using an ABI3730 sequencer. Data analysis was performed using plate manager application GeneMapper v5.2- 3730XL.</p></sec><sec id="s4d"><title>Histology</title><p>Peripheral tissues were dissected from, four 22 month old <italic>Hdh</italic><sup>Q150/Q150</sup> mice, four wild type littermate control mice, one 12 week old R6/2 and one wild type littermate control, that had been perfusion fixed with 4&#x00025; paraformaldehyde. The organs and tissues were removed for histological examination and the heart, kidneys, liver, spleen, quadriceps and testis weighed. Tissues were processed and embedded in paraffin wax and 5 &#x000b5;m sections were cut on an RM 2155 microtome (Leica Microsystems). A few sections from each tissue were stained with Harris's haematoxylin and eosin (H&#x00026;E) <xref ref-type="bibr" rid="pone.0008025-Bancroft1">&#x0005b;61&#x0005d;</xref>.</p></sec><sec id="s4e"><title>Immunohistochemistry</title><p>The remaining sections were immunoperoxidase stained with huntingtin antibody S830 <xref ref-type="bibr" rid="pone.0008025-Sathasivam3">&#x0005b;62&#x0005d;</xref>. Sections were dewaxed in histoclear (Agar Scientific), rehydrated, incubated in 4&#x00025; hydrogen peroxide for 10 mins, washed in dH<sub>2</sub>0, antigen retrieved by pressure cooking on high in 0.1 M Citric acid pH 6.0 for 7 min and washed in dH<sub>2</sub>O <xref ref-type="bibr" rid="pone.0008025-Bancroft1">&#x0005b;61&#x0005d;</xref>. Endogenous biotin was blocked using a Biotin Blocking kit (Vector Laboratories) and incubated in primary antibody (S830: sheep polyclonal; 1&#x02236;2000) in blocking solution (0.1 M Tris-HCl pH 7.5, 0.9&#x00025; NaCl (TBS) and 2&#x00025; bovine serum albumin (BSA)) at 4&#x000b0;C overnight, washed twice in TBS for 15 min and incubated for 1 h at RT in biotinylated horse anti-goat secondary antibody (Vector Laboratories) in blocking solution (1&#x02236;500). After washing with TBS, sections were incubated in ABC-HRP complex using the Vectastain Elite ABC kit (Vector Laboratories) as recommended by the manufacturer and then incubated with a 0.05&#x00025; solution 3,3-diaminobezidine (DAB) in 0.1 M Tris&#x02013;HCl pH 7.5. H<sub>2</sub>O<sub>2</sub> was added to 0.03&#x00025;, the colour allowed to develop for 10 min and the slices washed extensively in dH<sub>2</sub>O. Sections were counterstained with Methyl Green prior to viewing on an Axioskop 2 microscope (Zeiss) and images captured using an Axiocam camera, and Axiovision software (Zeiss).</p></sec><sec id="s4f"><title>Morphometry</title><p>The H&#x00026;E stained sections of the quadriceps muscle were examined and 10 random high power micrographs were taken for each animal. The images were then processed using Axiovision v4.6 software and the muscle fiber diameters estimated using the bound width measurement (minimum diameter).</p></sec><sec id="s4g"><title>Electron microscopy</title><p>Pancreatic samples from three additional 22 month old <italic>Hdh</italic><sup>Q150/Q150</sup> mice, 3 littermate controls and two 12 week old R6/2 mice were fixed in 2.5&#x00025; glutaraldehyde in 0.125 M phosphate buffer and processed for transmission electron microscopical examination. 60 nm sections were cut and stained with saturated aqueous uranyl acetate and Reynolds lead citrate <xref ref-type="bibr" rid="pone.0008025-Hayat1">&#x0005b;63&#x0005d;</xref> and imaged using a Jeol JEM 1230 transmission electron microscope.</p></sec><sec id="s4h"><title>Statistical analysis</title><p>Sample means were compared using the independent samples Student's <italic>t</italic>-test with the statistical package SPSS v 16.</p></sec></sec></body><back><ack><p>We thank Helen Cunliffe for genotyping and CAG repeat sizing.</p></ack><ref-list><title>References</title><ref id="pone.0008025-Bates1"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Bates</surname><given-names>GP</given-names></name><name><surname>Harper</surname><given-names>PS</given-names></name><name><surname>Jones</surname><given-names>AL</given-names></name></person-group><year>2002</year><article-title>Huntington's Disease. 3rd ed.</article-title><publisher-loc>Oxford</publisher-loc><publisher-name>Oxford University Press</publisher-name></mixed-citation></ref><ref id="pone.0008025-Huntingtons1"><label>2</label><mixed-citation publication-type="journal"><collab>Huntington's Disease Collaborative Research Group</collab><year>1993</year><article-title>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.</article-title><source>Cell</source><volume>72</volume><fpage>971</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">8458085</pub-id></mixed-citation></ref><ref id="pone.0008025-Rubinsztein1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Leggo</surname><given-names>J</given-names></name><name><surname>Coles</surname><given-names>R</given-names></name><name><surname>Almqvist</surname><given-names>E</given-names></name><name><surname>Biancalana</surname><given-names>V</given-names></name><etal/></person-group><year>1996</year><article-title>Phenotypic characterization of individuals with 30&#x02013;40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36&#x02013;39 repeats.</article-title><source>Am J Hum Genet</source><volume>59</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">8659522</pub-id></mixed-citation></ref><ref id="pone.0008025-Myers1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>RH</given-names></name></person-group><year>2004</year><article-title>Huntington's disease genetics.</article-title><source>NeuroRx</source><volume>1</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">15717026</pub-id></mixed-citation></ref><ref id="pone.0008025-Henley1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henley</surname><given-names>SM</given-names></name><name><surname>Wild</surname><given-names>EJ</given-names></name><name><surname>Hobbs</surname><given-names>NZ</given-names></name><name><surname>Frost</surname><given-names>C</given-names></name><name><surname>MacManus</surname><given-names>DG</given-names></name><etal/></person-group><year>2009</year><article-title>Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.</article-title><source>Mov Disord</source><volume>24</volume><fpage>932</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">19243073</pub-id></mixed-citation></ref><ref id="pone.0008025-Kloppel1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloppel</surname><given-names>S</given-names></name><name><surname>Henley</surname><given-names>SM</given-names></name><name><surname>Hobbs</surname><given-names>NZ</given-names></name><name><surname>Wolf</surname><given-names>RC</given-names></name><name><surname>Kassubek</surname><given-names>J</given-names></name><etal/></person-group><year>2009</year><article-title>Magnetic resonance imaging of Huntington's disease: preparing for clinical trials.</article-title><source>Neuroscience</source><volume>164</volume><fpage>205</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">19409230</pub-id></mixed-citation></ref><ref id="pone.0008025-DiFiglia1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiFiglia</surname><given-names>M</given-names></name><name><surname>Sapp</surname><given-names>E</given-names></name><name><surname>Chase</surname><given-names>KO</given-names></name><name><surname>Davies</surname><given-names>SW</given-names></name><name><surname>Bates</surname><given-names>GP</given-names></name><etal/></person-group><year>1997</year><article-title>Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.</article-title><source>Science</source><volume>277</volume><fpage>1990</fpage><lpage>1993</lpage><pub-id pub-id-type="pmid">9302293</pub-id></mixed-citation></ref><ref id="pone.0008025-Gutekunst1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutekunst</surname><given-names>CA</given-names></name><name><surname>Li</surname><given-names>SH</given-names></name><name><surname>Yi</surname><given-names>H</given-names></name><name><surname>Mulroy</surname><given-names>JS</given-names></name><name><surname>Kuemmerle</surname><given-names>S</given-names></name><etal/></person-group><year>1999</year><article-title>Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.</article-title><source>J Neurosci</source><volume>19</volume><fpage>2522</fpage><lpage>2534</lpage><pub-id pub-id-type="pmid">10087066</pub-id></mixed-citation></ref><ref id="pone.0008025-Menalled1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menalled</surname><given-names>L</given-names></name><name><surname>El-Khodor</surname><given-names>BF</given-names></name><name><surname>Patry</surname><given-names>M</given-names></name><name><surname>Suarez-Farinas</surname><given-names>M</given-names></name><name><surname>Orenstein</surname><given-names>SJ</given-names></name><etal/></person-group><year>2009</year><article-title>Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.</article-title><source>Neurobiol Dis</source><volume>35</volume><fpage>319</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">19464370</pub-id></mixed-citation></ref><ref id="pone.0008025-Mangiarini1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangiarini</surname><given-names>L</given-names></name><name><surname>Sathasivam</surname><given-names>K</given-names></name><name><surname>Seller</surname><given-names>M</given-names></name><name><surname>Cozens</surname><given-names>B</given-names></name><name><surname>Harper</surname><given-names>A</given-names></name><etal/></person-group><year>1996</year><article-title>Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.</article-title><source>Cell</source><volume>87</volume><fpage>493</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">8898202</pub-id></mixed-citation></ref><ref id="pone.0008025-Schilling1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilling</surname><given-names>G</given-names></name><name><surname>Becher</surname><given-names>MW</given-names></name><name><surname>Sharp</surname><given-names>AH</given-names></name><name><surname>Jinnah</surname><given-names>HA</given-names></name><name><surname>Duan</surname><given-names>K</given-names></name><etal/></person-group><year>1999</year><article-title>Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin &#x0005b;published erratum appears in Hum Mol Genet 1999 May;8(5):943&#x0005d;.</article-title><source>Hum Mol Genet</source><volume>8</volume><fpage>397</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">9949199</pub-id></mixed-citation></ref><ref id="pone.0008025-Lin1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Tallaksen-Greene</surname><given-names>S</given-names></name><name><surname>Chien</surname><given-names>WM</given-names></name><name><surname>Cearley</surname><given-names>JA</given-names></name><name><surname>Jackson</surname><given-names>WS</given-names></name><etal/></person-group><year>2001</year><article-title>Neurological abnormalities in a knock-in mouse model of Huntington's disease.</article-title><source>Hum Mol Genet</source><volume>10</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">11152661</pub-id></mixed-citation></ref><ref id="pone.0008025-Woodman1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodman</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>R</given-names></name><name><surname>Landles</surname><given-names>C</given-names></name><name><surname>Lupton</surname><given-names>MK</given-names></name><name><surname>Tse</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.</article-title><source>Brain Res Bull</source><volume>72</volume><fpage>83</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">17352931</pub-id></mixed-citation></ref><ref id="pone.0008025-Kuhn1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>A</given-names></name><name><surname>Goldstein</surname><given-names>DR</given-names></name><name><surname>Hodges</surname><given-names>A</given-names></name><name><surname>Strand</surname><given-names>AD</given-names></name><name><surname>Sengstag</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.</article-title><source>Hum Mol Genet</source><volume>16</volume><fpage>1845</fpage><lpage>1861</lpage><pub-id pub-id-type="pmid">17519223</pub-id></mixed-citation></ref><ref id="pone.0008025-Sathasivam1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathasivam</surname><given-names>K</given-names></name><name><surname>Hobbs</surname><given-names>C</given-names></name><name><surname>Turmaine</surname><given-names>M</given-names></name><name><surname>Mangiarini</surname><given-names>L</given-names></name><name><surname>Mahal</surname><given-names>A</given-names></name><etal/></person-group><year>1999</year><article-title>Formation of polyglutamine inclusions in non-CNS tissue.</article-title><source>Hum Mol Genet</source><volume>8</volume><fpage>813</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">10196370</pub-id></mixed-citation></ref><ref id="pone.0008025-Martin1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>B</given-names></name><name><surname>Golden</surname><given-names>E</given-names></name><name><surname>Carlson</surname><given-names>OD</given-names></name><name><surname>Pistell</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group><year>2009</year><article-title>Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.</article-title><source>Diabetes</source><volume>58</volume><fpage>318</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">18984744</pub-id></mixed-citation></ref><ref id="pone.0008025-Djousse1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djousse</surname><given-names>L</given-names></name><name><surname>Knowlton</surname><given-names>B</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Shoulson</surname><given-names>I</given-names></name><etal/></person-group><year>2002</year><article-title>Weight loss in early stage of Huntington's disease.</article-title><source>Neurology</source><volume>59</volume><fpage>1325</fpage><lpage>1330</lpage><pub-id pub-id-type="pmid">12427878</pub-id></mixed-citation></ref><ref id="pone.0008025-Aziz1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>NA</given-names></name><name><surname>van der Burg</surname><given-names>JM</given-names></name><name><surname>Landwehrmeyer</surname><given-names>GB</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name><name><surname>Stijnen</surname><given-names>T</given-names></name><etal/></person-group><year>2008</year><article-title>Weight loss in Huntington disease increases with higher CAG repeat number.</article-title><source>Neurology</source><volume>71</volume><fpage>1506</fpage><lpage>1513</lpage><pub-id pub-id-type="pmid">18981372</pub-id></mixed-citation></ref><ref id="pone.0008025-Lodi1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodi</surname><given-names>R</given-names></name><name><surname>Schapira</surname><given-names>AH</given-names></name><name><surname>Manners</surname><given-names>D</given-names></name><name><surname>Styles</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><etal/></person-group><year>2000</year><article-title>Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy.</article-title><source>Ann Neurol</source><volume>48</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">10894218</pub-id></mixed-citation></ref><ref id="pone.0008025-Busse1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname><given-names>ME</given-names></name><name><surname>Hughes</surname><given-names>G</given-names></name><name><surname>Wiles</surname><given-names>CM</given-names></name><name><surname>Rosser</surname><given-names>AE</given-names></name></person-group><year>2008</year><article-title>Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington's disease.</article-title><source>J Neurol</source><volume>255</volume><fpage>1534</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">19005627</pub-id></mixed-citation></ref><ref id="pone.0008025-Lalic1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalic</surname><given-names>NM</given-names></name><name><surname>Maric</surname><given-names>J</given-names></name><name><surname>Svetel</surname><given-names>M</given-names></name><name><surname>Jotic</surname><given-names>A</given-names></name><name><surname>Stefanova</surname><given-names>E</given-names></name><etal/></person-group><year>2008</year><article-title>Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion.</article-title><source>Arch Neurol</source><volume>65</volume><fpage>476</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">18413469</pub-id></mixed-citation></ref><ref id="pone.0008025-Panov1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panov</surname><given-names>AV</given-names></name><name><surname>Gutekunst</surname><given-names>CA</given-names></name><name><surname>Leavitt</surname><given-names>BR</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Burke</surname><given-names>JR</given-names></name><etal/></person-group><year>2002</year><article-title>Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.</article-title><source>Nat Neurosci</source><volume>5</volume><fpage>731</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">12089530</pub-id></mixed-citation></ref><ref id="pone.0008025-Squitieri1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squitieri</surname><given-names>F</given-names></name><name><surname>Cannella</surname><given-names>M</given-names></name><name><surname>Sgarbi</surname><given-names>G</given-names></name><name><surname>Maglione</surname><given-names>V</given-names></name><name><surname>Falleni</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation.</article-title><source>Mech Ageing Dev</source><volume>127</volume><fpage>217</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">16289240</pub-id></mixed-citation></ref><ref id="pone.0008025-Bjorkqvist1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjorkqvist</surname><given-names>M</given-names></name><name><surname>Petersen</surname><given-names>A</given-names></name><name><surname>Bacos</surname><given-names>K</given-names></name><name><surname>Isaacs</surname><given-names>J</given-names></name><name><surname>Norlen</surname><given-names>P</given-names></name><etal/></person-group><year>2006</year><article-title>Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease.</article-title><source>Hum Mol Genet</source><volume>15</volume><fpage>1713</fpage><lpage>1721</lpage><pub-id pub-id-type="pmid">16613897</pub-id></mixed-citation></ref><ref id="pone.0008025-Bjorkqvist2"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjorkqvist</surname><given-names>M</given-names></name><name><surname>Fex</surname><given-names>M</given-names></name><name><surname>Renstrom</surname><given-names>E</given-names></name><name><surname>Wierup</surname><given-names>N</given-names></name><name><surname>Petersen</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis.</article-title><source>Hum Mol Genet</source><volume>14</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">15649949</pub-id></mixed-citation></ref><ref id="pone.0008025-Powley1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powley</surname><given-names>TL</given-names></name><name><surname>Chi</surname><given-names>MM</given-names></name><name><surname>Baronowsky</surname><given-names>EA</given-names></name><name><surname>Phillips</surname><given-names>RJ</given-names></name></person-group><year>2005</year><article-title>Gastrointestinal tract innervation of the mouse: afferent regeneration and meal patterning after vagotomy.</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><volume>289</volume><fpage>R563</fpage><lpage>R574</lpage><pub-id pub-id-type="pmid">15831767</pub-id></mixed-citation></ref><ref id="pone.0008025-Sanberg1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanberg</surname><given-names>PR</given-names></name><name><surname>Fibiger</surname><given-names>HC</given-names></name><name><surname>Mark</surname><given-names>RF</given-names></name></person-group><year>1981</year><article-title>Body weight and dietary factors in Huntington's disease patients compared with matched controls.</article-title><source>Med J Aust</source><volume>1</volume><fpage>407</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">6454826</pub-id></mixed-citation></ref><ref id="pone.0008025-Davies1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>SW</given-names></name><name><surname>Turmaine</surname><given-names>M</given-names></name><name><surname>Cozens</surname><given-names>BA</given-names></name><name><surname>DiFiglia</surname><given-names>M</given-names></name><name><surname>Sharp</surname><given-names>AH</given-names></name><etal/></person-group><year>1997</year><article-title>Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.</article-title><source>Cell</source><volume>90</volume><fpage>537</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">9267033</pub-id></mixed-citation></ref><ref id="pone.0008025-Hockly1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockly</surname><given-names>E</given-names></name><name><surname>Woodman</surname><given-names>B</given-names></name><name><surname>Mahal</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Bates</surname><given-names>G</given-names></name></person-group><year>2003</year><article-title>Standardization and statistical approaches to therapeutic trials in the R6/2 mouse.</article-title><source>Brain Res Bull</source><volume>61</volume><fpage>469</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">13679245</pub-id></mixed-citation></ref><ref id="pone.0008025-Sewry1"><label>30</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sewry</surname><given-names>CA</given-names></name><name><surname>Dubowitz</surname><given-names>V</given-names></name></person-group><year>2001</year><article-title>Histochemistry and immunohistochemistry of muscle in health and disease.</article-title><person-group person-group-type="editor"><name><surname>Karpati</surname><given-names>G</given-names></name><name><surname>Hilton-Jones</surname><given-names>D</given-names></name><name><surname>Griggs</surname><given-names>RC</given-names></name></person-group><source>Disorders of voluntary muscle. 7th ed</source><publisher-loc>Cambridge</publisher-loc><publisher-name>Cambridge University Press</publisher-name><size units="page"/></mixed-citation></ref><ref id="pone.0008025-Saft1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saft</surname><given-names>C</given-names></name><name><surname>Zange</surname><given-names>J</given-names></name><name><surname>Andrich</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>K</given-names></name><name><surname>Lindenberg</surname><given-names>K</given-names></name><etal/></person-group><year>2005</year><article-title>Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.</article-title><source>Mov Disord</source><volume>20</volume><fpage>674</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">15704211</pub-id></mixed-citation></ref><ref id="pone.0008025-Ribchester1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribchester</surname><given-names>RR</given-names></name><name><surname>Thomson</surname><given-names>D</given-names></name><name><surname>Wood</surname><given-names>NI</given-names></name><name><surname>Hinks</surname><given-names>T</given-names></name><name><surname>Gillingwater</surname><given-names>TH</given-names></name><etal/></person-group><year>2004</year><article-title>Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.</article-title><source>Eur J Neurosci</source><volume>20</volume><fpage>3092</fpage><lpage>3114</lpage><pub-id pub-id-type="pmid">15579164</pub-id></mixed-citation></ref><ref id="pone.0008025-Kosinski1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosinski</surname><given-names>CM</given-names></name><name><surname>Schlangen</surname><given-names>C</given-names></name><name><surname>Gellerich</surname><given-names>FN</given-names></name><name><surname>Gizatullina</surname><given-names>Z</given-names></name><name><surname>Deschauer</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Myopathy as a first symptom of Huntington's disease in a Marathon runner.</article-title><source>Mov Disord</source><volume>22</volume><fpage>1637</fpage><lpage>1640</lpage><pub-id pub-id-type="pmid">17534945</pub-id></mixed-citation></ref><ref id="pone.0008025-Strand1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strand</surname><given-names>AD</given-names></name><name><surname>Aragaki</surname><given-names>AK</given-names></name><name><surname>Shaw</surname><given-names>D</given-names></name><name><surname>Bird</surname><given-names>T</given-names></name><name><surname>Holton</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Gene expression in Huntington's disease skeletal muscle: a potential biomarker.</article-title><source>Hum Mol Genet</source><volume>14</volume><fpage>1863</fpage><lpage>1876</lpage><pub-id pub-id-type="pmid">15888475</pub-id></mixed-citation></ref><ref id="pone.0008025-Chaturvedi1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname><given-names>RK</given-names></name><name><surname>Adhihetty</surname><given-names>P</given-names></name><name><surname>Shukla</surname><given-names>S</given-names></name><name><surname>Hennessy</surname><given-names>T</given-names></name><name><surname>Calingasan</surname><given-names>N</given-names></name><etal/></person-group><year>2009</year><article-title>Impaired PGC-1alpha function in muscle in Huntington's disease.</article-title><source>Hum Mol Genet</source><volume>18</volume><fpage>3048</fpage><lpage>3065</lpage><pub-id pub-id-type="pmid">19460884</pub-id></mixed-citation></ref><ref id="pone.0008025-Goodman1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>AO</given-names></name><name><surname>Murgatroyd</surname><given-names>PR</given-names></name><name><surname>Medina-Gomez</surname><given-names>G</given-names></name><name><surname>Wood</surname><given-names>NI</given-names></name><name><surname>Finer</surname><given-names>N</given-names></name><etal/></person-group><year>2008</year><article-title>The metabolic profile of early Huntington's disease&#x02013;a combined human and transgenic mouse study.</article-title><source>Exp Neurol</source><volume>210</volume><fpage>691</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">18284928</pub-id></mixed-citation></ref><ref id="pone.0008025-vanderBurg1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Burg</surname><given-names>JM</given-names></name><name><surname>Bacos</surname><given-names>K</given-names></name><name><surname>Wood</surname><given-names>NI</given-names></name><name><surname>Lindqvist</surname><given-names>A</given-names></name><name><surname>Wierup</surname><given-names>N</given-names></name><etal/></person-group><year>2008</year><article-title>Increased metabolism in the R6/2 mouse model of Huntington's disease.</article-title><source>Neurobiol Dis</source><volume>29</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17920283</pub-id></mixed-citation></ref><ref id="pone.0008025-Petersen1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>A</given-names></name><name><surname>Gil</surname><given-names>J</given-names></name><name><surname>Maat-Schieman</surname><given-names>ML</given-names></name><name><surname>Bjorkqvist</surname><given-names>M</given-names></name><name><surname>Tanila</surname><given-names>H</given-names></name><etal/></person-group><year>2005</year><article-title>Orexin loss in Huntington's disease.</article-title><source>Hum Mol Genet</source><volume>14</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15525658</pub-id></mixed-citation></ref><ref id="pone.0008025-Aziz2"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>NA</given-names></name><name><surname>Swaab</surname><given-names>DF</given-names></name><name><surname>Pijl</surname><given-names>H</given-names></name><name><surname>Roos</surname><given-names>RA</given-names></name></person-group><year>2007</year><article-title>Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications.</article-title><source>Rev Neurosci</source><volume>18</volume><fpage>223</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">18019608</pub-id></mixed-citation></ref><ref id="pone.0008025-Bjorkqvist3"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjorkqvist</surname><given-names>M</given-names></name><name><surname>Wild</surname><given-names>EJ</given-names></name><name><surname>Thiele</surname><given-names>J</given-names></name><name><surname>Silvestroni</surname><given-names>A</given-names></name><name><surname>Andre</surname><given-names>R</given-names></name><etal/></person-group><year>2008</year><article-title>A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.</article-title><source>J Exp Med</source><volume>205</volume><fpage>1869</fpage><lpage>1877</lpage><pub-id pub-id-type="pmid">18625748</pub-id></mixed-citation></ref><ref id="pone.0008025-Lanska1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanska</surname><given-names>DJ</given-names></name><name><surname>Lavine</surname><given-names>L</given-names></name><name><surname>Lanska</surname><given-names>MJ</given-names></name><name><surname>Schoenberg</surname><given-names>BS</given-names></name></person-group><year>1988</year><article-title>Huntington's disease mortality in the United States.</article-title><source>Neurology</source><volume>38</volume><fpage>769</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">2966305</pub-id></mixed-citation></ref><ref id="pone.0008025-Sorensen1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>SA</given-names></name><name><surname>Fenger</surname><given-names>K</given-names></name></person-group><year>1992</year><article-title>Causes of death in patients with Huntington's disease and in unaffected first degree relatives.</article-title><source>J Med Genet</source><volume>29</volume><fpage>911</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">1479606</pub-id></mixed-citation></ref><ref id="pone.0008025-Mihm1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihm</surname><given-names>MJ</given-names></name><name><surname>Amann</surname><given-names>DM</given-names></name><name><surname>Schanbacher</surname><given-names>BL</given-names></name><name><surname>Altschuld</surname><given-names>RA</given-names></name><name><surname>Bauer</surname><given-names>JA</given-names></name><etal/></person-group><year>2007</year><article-title>Cardiac dysfunction in the R6/2 mouse model of Huntington's disease.</article-title><source>Neurobiol Dis</source><volume>25</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">17126554</pub-id></mixed-citation></ref><ref id="pone.0008025-Pattison1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pattison</surname><given-names>JS</given-names></name><name><surname>Sanbe</surname><given-names>A</given-names></name><name><surname>Maloyan</surname><given-names>A</given-names></name><name><surname>Osinska</surname><given-names>H</given-names></name><name><surname>Klevitsky</surname><given-names>R</given-names></name><etal/></person-group><year>2008</year><article-title>Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure.</article-title><source>Circulation</source><volume>117</volume><fpage>2743</fpage><lpage>2751</lpage><pub-id pub-id-type="pmid">18490523</pub-id></mixed-citation></ref><ref id="pone.0008025-Hunt1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>MJ</given-names></name><name><surname>Morton</surname><given-names>AJ</given-names></name></person-group><year>2005</year><article-title>Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.</article-title><source>Exp Brain Res</source><volume>166</volume><fpage>220</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">16034568</pub-id></mixed-citation></ref><ref id="pone.0008025-Andreassen1"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreassen</surname><given-names>OA</given-names></name><name><surname>Dedeoglu</surname><given-names>A</given-names></name><name><surname>Stanojevic</surname><given-names>V</given-names></name><name><surname>Hughes</surname><given-names>DB</given-names></name><name><surname>Browne</surname><given-names>SE</given-names></name><etal/></person-group><year>2002</year><article-title>Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression.</article-title><source>Neurobiol Dis</source><volume>11</volume><fpage>410</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">12586550</pub-id></mixed-citation></ref><ref id="pone.0008025-Josefsen1"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Josefsen</surname><given-names>K</given-names></name><name><surname>Nielsen</surname><given-names>MD</given-names></name><name><surname>Jorgensen</surname><given-names>KH</given-names></name><name><surname>Bock</surname><given-names>T</given-names></name><name><surname>Norremolle</surname><given-names>A</given-names></name><etal/></person-group><year>2008</year><article-title>Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.</article-title><source>J Neuroendocrinol</source><volume>20</volume><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">18034868</pub-id></mixed-citation></ref><ref id="pone.0008025-Hurlbert1"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurlbert</surname><given-names>MS</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Wasmeier</surname><given-names>C</given-names></name><name><surname>Kaddis</surname><given-names>FG</given-names></name><name><surname>Hutton</surname><given-names>JC</given-names></name><etal/></person-group><year>1999</year><article-title>Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes.</article-title><source>Diabetes</source><volume>48</volume><fpage>649</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">10078572</pub-id></mixed-citation></ref><ref id="pone.0008025-Luesse1"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luesse</surname><given-names>HG</given-names></name><name><surname>Schiefer</surname><given-names>J</given-names></name><name><surname>Spruenken</surname><given-names>A</given-names></name><name><surname>Puls</surname><given-names>C</given-names></name><name><surname>Block</surname><given-names>F</given-names></name><etal/></person-group><year>2001</year><article-title>Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus.</article-title><source>Behav Brain Res</source><volume>126</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">11704263</pub-id></mixed-citation></ref><ref id="pone.0008025-Fain1"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fain</surname><given-names>JN</given-names></name><name><surname>Del Mar</surname><given-names>NA</given-names></name><name><surname>Meade</surname><given-names>CA</given-names></name><name><surname>Reiner</surname><given-names>A</given-names></name><name><surname>Goldowitz</surname><given-names>D</given-names></name></person-group><year>2001</year><article-title>Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation.</article-title><source>Hum Mol Genet</source><volume>10</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">11152662</pub-id></mixed-citation></ref><ref id="pone.0008025-Duan1"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Ware</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>XJ</given-names></name><etal/></person-group><year>2003</year><article-title>Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice.</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><fpage>2911</fpage><lpage>2916</lpage><pub-id pub-id-type="pmid">12589027</pub-id></mixed-citation></ref><ref id="pone.0008025-Bacos1"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacos</surname><given-names>K</given-names></name><name><surname>Bjorkqvist</surname><given-names>M</given-names></name><name><surname>Petersen</surname><given-names>A</given-names></name><name><surname>Luts</surname><given-names>L</given-names></name><name><surname>Maat-Schieman</surname><given-names>ML</given-names></name><etal/></person-group><year>2008</year><article-title>Islet beta-cell area and hormone expression are unaltered in Huntington's disease.</article-title><source>Histochem Cell Biol</source><volume>129</volume><fpage>623</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">18259770</pub-id></mixed-citation></ref><ref id="pone.0008025-Petersen2"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>A</given-names></name><name><surname>Bjorkqvist</surname><given-names>M</given-names></name></person-group><year>2006</year><article-title>Hypothalamic-endocrine aspects in Huntington's disease.</article-title><source>Eur J Neurosci</source><volume>24</volume><fpage>961</fpage><lpage>967</lpage><pub-id pub-id-type="pmid">16925587</pub-id></mixed-citation></ref><ref id="pone.0008025-Saleh1"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleh</surname><given-names>N</given-names></name><name><surname>Moutereau</surname><given-names>S</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Krystkowiak</surname><given-names>P</given-names></name><name><surname>Azulay</surname><given-names>JP</given-names></name><etal/></person-group><year>2009</year><article-title>Neuroendocrine disturbances in Huntington's disease.</article-title><source>PLoS ONE</source><volume>4</volume><fpage>e4962</fpage><comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0004962">10.1371/journal.pone.0004962</ext-link></comment><pub-id pub-id-type="pmid">19319184</pub-id></mixed-citation></ref><ref id="pone.0008025-VanRaamsdonk1"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Raamsdonk</surname><given-names>JM</given-names></name><name><surname>Murphy</surname><given-names>Z</given-names></name><name><surname>Selva</surname><given-names>DM</given-names></name><name><surname>Hamidizadeh</surname><given-names>R</given-names></name><name><surname>Pearson</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>Testicular degeneration in Huntington disease.</article-title><source>Neurobiol Dis</source><volume>26</volume><fpage>512</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">17433700</pub-id></mixed-citation></ref><ref id="pone.0008025-Papalexi1"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Persson</surname><given-names>A</given-names></name><name><surname>Bjorkqvist</surname><given-names>M</given-names></name><name><surname>Petersen</surname><given-names>A</given-names></name><name><surname>Woodman</surname><given-names>B</given-names></name><etal/></person-group><year>2005</year><article-title>Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.</article-title><source>Eur J Neurosci</source><volume>22</volume><fpage>1541</fpage><lpage>1546</lpage><pub-id pub-id-type="pmid">16190907</pub-id></mixed-citation></ref><ref id="pone.0008025-Markianos1"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markianos</surname><given-names>M</given-names></name><name><surname>Panas</surname><given-names>M</given-names></name><name><surname>Kalfakis</surname><given-names>N</given-names></name><name><surname>Vassilopoulos</surname><given-names>D</given-names></name></person-group><year>2005</year><article-title>Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia.</article-title><source>Ann Neurol</source><volume>57</volume><fpage>520</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">15786456</pub-id></mixed-citation></ref><ref id="pone.0008025-Weydt1"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weydt</surname><given-names>P</given-names></name><name><surname>Pineda</surname><given-names>VV</given-names></name><name><surname>Torrence</surname><given-names>AE</given-names></name><name><surname>Libby</surname><given-names>RT</given-names></name><name><surname>Satterfield</surname><given-names>TF</given-names></name><etal/></person-group><year>2006</year><article-title>Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.</article-title><source>Cell Metab</source><volume>4</volume><fpage>349</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">17055784</pub-id></mixed-citation></ref><ref id="pone.0008025-Phan1"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>J</given-names></name><name><surname>Hickey</surname><given-names>MA</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Chesselet</surname><given-names>MF</given-names></name><name><surname>Reue</surname><given-names>K</given-names></name></person-group><year>2009</year><article-title>Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models.</article-title><source>Hum Mol Genet</source><volume>18</volume><fpage>1006</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">19124532</pub-id></mixed-citation></ref><ref id="pone.0008025-Sathasivam2"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathasivam</surname><given-names>K</given-names></name><name><surname>Lane</surname><given-names>A</given-names></name><name><surname>Legleiter</surname><given-names>J</given-names></name><name><surname>Warley</surname><given-names>A</given-names></name><name><surname>Woodman</surname><given-names>B</given-names></name><etal/></person-group><year>2009</year><article-title>Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease.</article-title><source>Hum Mol Genet. in press</source></mixed-citation></ref><ref id="pone.0008025-Bancroft1"><label>61</label><mixed-citation publication-type="other"><person-group person-group-type="editor"><name><surname>Bancroft</surname><given-names>JD</given-names></name><name><surname>Gamble</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Theory and practice of histological techniques. 5th ed: Churchill Livingstone.</article-title></mixed-citation></ref><ref id="pone.0008025-Sathasivam3"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathasivam</surname><given-names>K</given-names></name><name><surname>Woodman</surname><given-names>B</given-names></name><name><surname>Mahal</surname><given-names>A</given-names></name><name><surname>Bertaux</surname><given-names>F</given-names></name><name><surname>Wanker</surname><given-names>EE</given-names></name><etal/></person-group><year>2001</year><article-title>Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients.</article-title><source>Hum Mol Genet</source><volume>10</volume><fpage>2425</fpage><lpage>2435</lpage><pub-id pub-id-type="pmid">11689489</pub-id></mixed-citation></ref><ref id="pone.0008025-Hayat1"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayat</surname><given-names>MA</given-names></name></person-group><year>2000</year><article-title>Principals and techniques of electron microscopy: biological applications: Cambridge Press.</article-title></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The R6/2 mice are licensed by King's College London for commercial use</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by grants from Medical Research Council (G9800001), Wellcome Trust (066270), CHDI Foundation, and Huntington's Disease Society of America Coalition for the Cure to GPB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>